01:29 PM EDT, 03/25/2024 (MT Newswires) -- Biodesix ( BDSX ) said Monday it entered into a new master collaborative research agreement with Memorial Sloan Kettering Cancer Center to develop diagnostic tests for cancer treatment.

Biodesix ( BDSX ) said it will utilize its genomics, proteomics, and data mining capabilities to develop and commercialize oncology biomarker assays in the collaboration, adding that Bio-Rad Laboratories ( BIO/B ) will supply its digital PCR assay technology.

Biodesix ( BDSX ) shares were up more than 5% in recent trading.

Price: 1.45, Change: +0.07, Percent Change: +5.03